Proteomic analysis identifies highly expressed plasma membrane proteins for detection and therapeutic targeting of specific breast cancer subtypes

[1]  M. Apicella,et al.  Targeted therapies for gastric cancer: failures and hopes from clinical trials , 2017, Oncotarget.

[2]  E. Mardis,et al.  A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen , 2012, Clinical Cancer Research.

[3]  J. Swinnen,et al.  ATP-citrate lyase: a key player in cancer metabolism. , 2012, Cancer research.

[4]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[5]  J. Hampe,et al.  Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2) , 2009, Oncogene.

[6]  F. Lang,et al.  Downregulation of endometrial mesenchymal marker SUSD2 causes cell senescence and cell death in endometrial carcinoma cells , 2017, PloS one.

[7]  Hong Wang,et al.  The estrogen-responsive Agr2 gene regulates mammary epithelial proliferation and facilitates lobuloalveolar development. , 2012, Developmental biology.

[8]  B. Grallert,et al.  Activation of Gcn2 in response to different stresses , 2017, PloS one.

[9]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Graeber,et al.  Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer , 2018, Proceedings of the National Academy of Sciences.

[11]  E. Levin,et al.  Nature of functional estrogen receptors at the plasma membrane. , 2006, Molecular endocrinology.

[12]  H. Lincet,et al.  The reduced concentration of citrate in cancer cells: An indicator of cancer aggressiveness and a possible therapeutic target. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[13]  Hailin Tang,et al.  AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer , 2017, Journal of Experimental & Clinical Cancer Research.

[14]  The downregulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma , 2014, Molecular and Cellular Biochemistry.

[15]  A. Khaled,et al.  Targeting chaperonin containing TCP1 (CCT) as a molecular therapeutic for small cell lung cancer , 2017, Oncotarget.

[16]  Jayanta Debnath,et al.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.

[17]  Amit Kumar,et al.  The eEF1A Proteins: At the Crossroads of Oncogenesis, Apoptosis, and Viral Infections , 2015, Front. Oncol..

[18]  M. Loda,et al.  Fatty acid synthase as a potential therapeutic target in cancer. , 2010, Future oncology.

[19]  V. V. Zakharov,et al.  Ion channel activity of brain abundant protein BASP1 in planar lipid bilayers , 2011, The FEBS journal.

[20]  Masaru Tomita,et al.  emPAI Calc - for the estimation of protein abundance from large-scale identification data by liquid chromatography-tandem mass spectrometry , 2010, Bioinform..

[21]  B. Vojtesek,et al.  AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients , 2013, Disease markers.

[22]  T. H. van der Kwast,et al.  Quantitative Proteomics Reveals That Enzymes of the Ketogenic Pathway Are Associated with Prostate Cancer Progression* , 2013, Molecular & Cellular Proteomics.

[23]  J. Yates,et al.  Plasma Membrane Proteomics of Human Breast Cancer Cell Lines Identifies Potential Targets for Breast Cancer Diagnosis and Treatment , 2014, PloS one.

[24]  E. Cuyás,et al.  Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. , 2017, Histology and histopathology.

[25]  Fang Zhao,et al.  The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker , 2013, Breast Cancer Research.

[26]  C. Print,et al.  AHNAK is downregulated in melanoma, predicts poor outcome, and may be required for the expression of functional cadherin-1 , 2016, Melanoma research.

[27]  Di Yu,et al.  Axon growth and guidance genes identify T‐dependent germinal centre B cells , 2008, Immunology and cell biology.

[28]  J. Russo,et al.  Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. , 1990, Cancer research.

[29]  T. Yoshimine,et al.  The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers , 2014, International journal of oncology.

[30]  José A. Dianes,et al.  2016 update of the PRIDE database and its related tools , 2015, Nucleic Acids Res..

[31]  R. Sandberg,et al.  Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. M. Morré,et al.  Aqueous two-phase partition applied to the isolation of plasma membranes and Golgi apparatus from cultured mammalian cells. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[33]  C. Perou,et al.  Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures , 2014, Breast Cancer Research and Treatment.

[34]  Jian-Ting Zhang,et al.  Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. , 2010, International journal of biochemistry and molecular biology.

[35]  Charles M. Perou,et al.  A Comparison of Gene Expression Signatures from Breast Tumors and Breast Tissue Derived Cell Lines , 2002, Disease markers.

[36]  Vandana G Abramson,et al.  Molecular Heterogeneity of Triple-Negative Breast Cancer , 2014, Current Breast Cancer Reports.

[37]  B. Gusterson,et al.  Involvement of axonal guidance proteins and their signaling partners in the developing mouse mammary gland , 2006, Journal of cellular physiology.

[38]  W. Ritchie,et al.  ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer , 2015, Oncogene.

[39]  Daniel W Chan,et al.  Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. , 2009, Neoplasia.

[40]  J. Yates,et al.  An automated multidimensional protein identification technology for shotgun proteomics. , 2001, Analytical chemistry.

[41]  Tsviya Olender,et al.  GeneCards Version 3: the human gene integrator , 2010, Database J. Biol. Databases Curation.

[42]  John D. Venable,et al.  MS1, MS2, and SQT-three unified, compact, and easily parsed file formats for the storage of shotgun proteomic spectra and identifications. , 2004, Rapid communications in mass spectrometry : RCM.

[43]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[44]  José A. Dianes,et al.  2016 update of the PRIDE database and its related tools , 2016, Nucleic Acids Res..

[45]  Edi Brogi,et al.  Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs , 2011, Nature Medicine.

[46]  E. Friauf,et al.  Proteomic Analysis of Brain Plasma Membranes Isolated by Affinity Two-phase Partitioning*S , 2006, Molecular & Cellular Proteomics.

[47]  J. Yates,et al.  Protein disulfide isomerase serves as a molecular chaperone to maintain estrogen receptor alpha structure and function. , 2006, Molecular endocrinology.

[48]  Tingting Li,et al.  SUSD2 is frequently downregulated and functions as a tumor suppressor in RCC and lung cancer , 2016, Tumor Biology.

[49]  Icard Philippe,et al.  The Reduced Concentration of Citrate in Cancer Cells: An Indicator of Cancer Aggressiveness and a Possible Therapeutic Target , 2016 .

[50]  T. Kislinger,et al.  Cell-surface proteomics for the identification of novel therapeutic targets in cancer , 2018, Expert review of proteomics.

[51]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[52]  Michael K. Coleman,et al.  Statistical analysis of membrane proteome expression changes in Saccharomyces cerevisiae. , 2006, Journal of proteome research.

[53]  Joshua E. Elias,et al.  Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. , 2003, Journal of proteome research.

[54]  John D. Venable,et al.  ProLuCID: An improved SEQUEST-like algorithm with enhanced sensitivity and specificity. , 2015, Journal of proteomics.

[55]  C. Deng,et al.  Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype , 2017, Oncotarget.

[56]  J. Khan,et al.  Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers , 2012, Front. Oncol..

[57]  J. Yates,et al.  Protein Disulfide Isomerase Serves as a Molecular Chaperone to Maintain Estrogen Receptor α Structure and Function , 2006 .

[58]  M. Gierliński,et al.  Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib , 2017, bioRxiv.

[59]  Rick L. Evans,et al.  Multiple Functions of Sushi Domain Containing 2 (SUSD2) in Breast Tumorigenesis , 2012, Molecular Cancer Research.

[60]  A. Brufsky.  Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. , 2017, Cancer treatment reviews.

[61]  M. Hung,et al.  The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer , 2016, Cancer and Metastasis Reviews.

[62]  M. Apicella,et al.  Targeted therapies for gastric cancer: failures and hopes from clinical trials , 2017, Oncotarget.

[63]  J. Yates,et al.  Integration of Breast Cancer Secretomes with Clinical Data Elucidates Potential Serum Markers for Disease Detection, Diagnosis, and Prognosis , 2016, PloS one.

[64]  E. Lundberg,et al.  Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.

[65]  J. Stap,et al.  Tripeptidyl Peptidase II Mediates Levels of Nuclear Phosphorylated ERK1 and ERK2* , 2015, Molecular & Cellular Proteomics.